Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
Zacks Investment Research on MSN1d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...
Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors and ...
Zacks Investment Research on MSN2d
DXCM Stock Gains Following New Data on Upcoming G7 CGM SensorDexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...
A study that looks into the potential of wearables to non-invasively measure blood glucose has come up with promising results ...
The 15.5-day Dexcom G7 continuous glucose monitor (CGM) demonstrated high accuracy and safety in adults with diabetes, meeting and exceeding integrated CGM performance goals.
Dexcom is preparing to launch a 15-day version of its G7 continuous glucose monitor, based on data presented Thursday at the Advanced Technologies & Treatments for Diabetes conference. Dexcom ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback